Literature DB >> 700321

Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis.

J G Bartlett, N Moon, T W Chang, N Taylor, A B Onderdonk.   

Abstract

Tissue cultures were performed on stools from 189 patients to detect a cytopathic toxin which is neutralized by Clostridium sordellii antitoxin. Specimens satisfying these criteria were considered positive in the tissue culture assay. Stools from 26 of 27 patients with antibiotic-associated pseudomembranous colitis were positive and 16 of these specimens showed toxin titers of 10(-3) dilutions or greater. The tissue culture assay was positive with specimens from 9 of 63 patients with antibiotic-associated diarrhea without documented pseudomembrane formation. Stools from patients with neonatal necrotizing enterocolitis, ulcerative colitis, and healthy controls were uniformly negative in this assay. Cultures were performed on stools from 38 patients with antibiotic-associated diarrhea or colitis to detect clostridia which produce a cytopathic toxin in vitro. Clostridium difficile was recovered from 6 of 8 specimens which were positive in the tissue culture assay and 5 of 30 which were negative in this assay. C. sordellii was recovered in a single specimen. One hundred and nine clostridia strains were tested in the tissue culture assay and C. difficile was the only species which produced a cytopathic toxin. All strains of this organism were positive in the tissue culture assay and, in each instance, cytotoxicity was neutralized by C. sordellii antitoxin. These results indicate that C. difficile is the major cause of antibiotic-associated pseudomembranous colitis and offer an explanation for previous studies showing that the cytotoxin of stools from these patients is neutralized by C, sordellii antitoxin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 700321

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  142 in total

1.  Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo.

Authors:  M C Barc; C Depitre; G Corthier; A Collignon; W J Su; P Bourlioux
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Ultrasonic and CT findings in penicillin-induced nonpseudomembranous colitis.

Authors:  T Matsumoto; M Iida; T Matsui; K Yoshida; T Sakai; Y Kimura; M Fujishima
Journal:  Gastrointest Radiol       Date:  1990

3.  Binary toxin and its clinical importance in Clostridium difficile infection, Belgium.

Authors:  T Pilate; J Verhaegen; M Van Ranst; V Saegeman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-08       Impact factor: 3.267

4.  Horizontal transfer of erythromycin resistance from Clostridium difficile to Butyrivibrio fibrisolvens.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Paola Mastrantonio
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 5.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 6.  Surgical Management of Clostridium difficile Colitis.

Authors:  Ann K Seltman
Journal:  Clin Colon Rectal Surg       Date:  2012-12

Review 7.  Toxigenic clostridia.

Authors:  C L Hatheway
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

8.  Antitoxin production in antibiotic-associated colitis?

Authors:  A H Lishman; I J Al-Jumaili; C O Record
Journal:  J Clin Pathol       Date:  1981-04       Impact factor: 3.411

9.  Presence of Clostridium difficile toxin in guinea pigs with penicillin-associated colitis.

Authors:  S W Rothman
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

10.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.